Uncategorized
Lucentis achieves visual, anatomic gains in 5 trials
BOSTON —David Eichenbaum, MD, and colleagues recapped the effects of Lucentis on retinal vein occlusion in takeaway points from five large clinical trials in a poster presented here at the American Society of Retina Specialists meeting.The BRAVO, SHORE and CRUISE trials all studied efficacy and safety of monthly and as-needed ranibizumab (Lucentis, Genentech) treatment for patients with retinal vein occlusion, and the BRIGHTER and CRYSTAL studies looked at efficacy and safety of ranibizumab in patients with retinal vein occlusion with and without macular ischemia.